Remove 2029 Remove Diabetes Remove Packaging
article thumbnail

Novo Nordisk plans multi-billion Denmark manufacturing expansion

European Pharmaceutical Review

According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging. The construction projects will be finalised from the end of 2025 through to 2029. Most of the investment will be focused on API capacity.

Packaging 111
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

The bill still must pass the Senate, and moreover, how uninsured people with diabetes will deal with steep prices still remains a question. CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). In-house manufacturing the norm.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Other drugs are set to face competition too, with both MSD’s Keytruda (pembrolizumab) and Johnson & Johnson’s (J&J) Darzalex/Faspro (daratumumab and hyaluronidase-fihj) losing US exclusivity by 2029, representing a particular headwind in oncology. How will RFK Jr’s American dream for vaccines play out?